Q32 Bio Inc. (QTTB), a clinical-stage biotechnology company developing treatments for alopecia areata and other autoimmune and inflammatory diseases, reported third-quarter 2026 financial results and provided updates on its bempikibart development program.
Company Profile
Q32 Bio is developing therapies targeting regulators of the adaptive immune system. Its lead candidate, bempikibart, is a fully human antibody designed to block IL-7 and TSLP signaling for the treatment of alopecia areata (AA).
Clinical And Pipeline Updates
In September 2026, Q32 Bio presented additional 36-week results and 16-week off-drug findings from Part B of its Phase 2a SIGNAL-AA trial at the EADV Congress 2026.
The study evaluated bempikibart in 33 patients with severe or very severe alopecia areata.
At Week 36, patients in the prespecified modified intent-to-treat analysis showed a mean 35.3% reduction in Severity of Alopecia Tool (SALT) scores from baseline.
Additionally, 40% of patients in the modified intent-to-treat analysis achieved a SALT-20 response, indicating at least 80% scalp hair coverage. In the overall intent-to-treat population, 30.3% achieved this response.
During the 16-week off-drug peri...